Table 2.
Summary of characteristics of the included studies
| Molecular POCTs | Antigen-based POCTs | |
|---|---|---|
| Number of studies | 26 | 97 |
| Number of retrospective studies | 9 | 21 |
| Number of prospective studies | 17 | 76 |
| Number of individual evaluations | 44 | 312 |
| Number of individual commercial tests | 16 | 36 |
| Total population | 11 675 | 82 093 |
| Males, % (n/N) | 51.2% (387/756a) | 47.4% (25 686/54 224a) |
| Adults, % (n/N) | 99.9% (11 673/11 675) | 93.1% (76 412/82 093) |
| Children, % (n/N) | 0.01% (2/11 675) | 6.9% (5681/82 093) |
| Number of IFU conforming evaluations | 18 | 58 |
| Number of self-sampling evaluations | 1 | 9 |
| Number of self-testing evaluations | 0 | 2 |
| Number of non–peer-reviewed studies | 2 | 23 |
IFU, instructions for use; POCT, point-of-care test.
a
These numbers correspond to the population that had available data.